Prospective Evaluation of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: The Stenting Of Saphenous Vein Grafts Xience V Angiographic Study (SOS-Xience V).

Trial Profile

Prospective Evaluation of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: The Stenting Of Saphenous Vein Grafts Xience V Angiographic Study (SOS-Xience V).

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Oct 2012

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms SOS-Xienc-V
  • Most Recent Events

    • 15 Jul 2011 Planned end date changed from 1 Jul 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 02 Aug 2010 Planned end date changed from 1 May 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 02 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top